Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
University of Heidelberg Medical Center
Amgen
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Radiation Therapy Oncology Group
Alliance for Clinical Trials in Oncology
Vifor Pharma
Vanderbilt-Ingram Cancer Center
Mayo Clinic